Alivus Life Q4 Results Preview: Earnings Growth, Key Expectations & Outlook

Fri Mar 20 2026

Alivus Life Sciences Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Alivus Life Sciences was listed on the National Stock Exchange (NSE) on 06-Aug-2021. Alivus Life Sciences share has its face value of 2 per share, and its NSE symbol is ALIVUS. The company operates in the Healthcare sector and primarily belongs to the Pharmaceuticals industry.

Table of Contents

Alivus Life Sciences Q4 Results 2026 Preview

Alivus Life Sciences Q4 FY26 revenue is expected to be around Moderate Growth Expected, representing a 10-13% YoY increase compared to the same quarter last year.
Profit After Tax, or PAT, is projected to rise 11-15% YoY.
EBITDA to rise 10-14%.
Alivus Life Sciences is expected to show Moderate Growth Expected in its revenue.

Click and Sign Up to Get Live Updates on Q4 Results

Alivus Life Sciences Share Performance

Over the past six months, Alivus Life Sciences share price has Up by 20% to 936.8.
Moreover, over the past year, the stock has Up by 34%
Despite this weak short-term performance, Alivus Life Sciences stock has delivered a financially sound 160% return over the past 5 years.
As of today, 20-03-2026, the Alivus Life Sciences share price is trading at 936.8 per share.

Key Factors to Watch for Alivus Life Sciences Q4 Results FY26

Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.

About Alivus Life Sciences

Alivus Life Sciences develops and markets generic and specialty pharmaceuticals, serving both domestic and international markets. Its product portfolio spans key therapeutic areas including cardiovascular, anti-diabetic, and central nervous system segments, positioning it as a diversified healthcare provider.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Final Thoughts

Alivus Life Sciences is gear up to announce its Q4 FY26 results. Analysts expect 10-13% revenue growth, a 11-15% rise in PAT, and a 10-14% rise in EBITDA. Alivus Life Sciences focuses on revenue growth from order execution, margin improvement, a strong order book, and management.

Stay informed with Univest blogs to get real-time updates on Alivus Life Sciences Q4 results FY26.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.